Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Leerink Partnrs

Leerink Partnrs upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Friday,Zacks.com reports.

Several other analysts have also recently weighed in on FULC. HC Wainwright reiterated a "neutral" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective for the company in a research note on Thursday, May 15th. Finally, Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $4.00 to $12.00 in a research note on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $6.29.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock traded up $0.36 during midday trading on Friday, hitting $7.26. 421,896 shares of the company were exchanged, compared to its average volume of 968,280. The firm has a market capitalization of $391.83 million, a P/E ratio of -23.42 and a beta of 2.29. The firm's 50 day moving average price is $4.24 and its two-hundred day moving average price is $3.97. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. Analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of FULC. Strs Ohio bought a new position in shares of Fulcrum Therapeutics in the first quarter valued at $263,000. Acadian Asset Management LLC boosted its position in shares of Fulcrum Therapeutics by 865.0% in the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock valued at $989,000 after acquiring an additional 308,854 shares during the period. Jane Street Group LLC lifted its position in Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company's stock valued at $339,000 after purchasing an additional 45,157 shares during the last quarter. Exome Asset Management LLC raised its stake in shares of Fulcrum Therapeutics by 143.0% during the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company's stock worth $1,985,000 after acquiring an additional 405,538 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Fulcrum Therapeutics during the first quarter worth approximately $425,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.